mouse model of Patient's MBC shows interesting similarity

http://www.sciencenewsline.com/summary/2013091923340031.html


This article goes over current TNBC treatment.   It offer hopes without the reality check that the so called "double"ed PFS probably means a few additional months.    Complete pathological response as experienced by this patient featured remains a "miracle", not the expected.
http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/2157

Perjeta approved Neoadjuvant use

http://www.onclive.com/web-exclusives/In-Historic-Vote-on-Pertuzumab-ODAC-Suggests-Approval-of-First-Neoadjuvant-Regimen-for-Cancer

Despite my reservation for adjuvant drug research, neoadjuvant regimen is a different thing and much more exciting development to watch, and has the potential to revolutionalize and speed up cancer research.


http://www.cancernetwork.com/conference-reports/asco2013/breast-cancer-symposium/content/article/10165/2157691

How a neoadjuvant studies shows that biomarkers changed during the course of early breast cancer therapy.


http://www.inspire.com/groups/advanced-breast-cancer/discussion/long-interesting-clinical-trials/

Someone on inspire posted a lot of interesting clinical trials collated list.

Entinostat breakthrough status

http://www.onclive.com/web-exclusives/Breakthrough-Designation-Granted-to-Entinostat-for-Advanced-Breast-Cancer

Quote:
In a March 2012 follow-up analysis published in the Journal of Clinical Oncology, the median PFS was 4.3 months versus 2.3 months, for entinostat and placebo, respectively (HR = 0.73; P = 0.06). In patients resistant to NSAIs (n = 45), the median PFS was 3.72 months compared to 1.78 months, in favor of the combination (HR = 0.47). - 

The median overall survival in the combination arm was 28.1 months compared to 19.8 months in the exemestane arm (HR = 0.59; P = 0.036). In a subset of patients (n = 49) with increased protein acetylation, the median PFS with the combination was 8.5 months compared with 2.8 months for patients without acetylation (HR = 0.32). 


My comment: Results are not terribly impressive.  But if this could be comboed with other targetted drug then this could be good.   

The key is the test for "protein acetylation"  (49/130).   The other patients might not have benefitted at all.   While the patients with increased protein acetylation (49/130)  seem to benefit at a much higher rate.



In other news:   Breast Cancer Index (BCI) Gene fingerprint identifies subset of HR+ EBC women at risk for 5+yr recurrence.   Lancet Oncology:
http://www.newsday.com/news/health/researchers-focus-on-likelihood-of-breast-cancer-recurrence-1.6056863

RealTime imaging of brain tumor using SRS

http://www.medicaldaily.com/new-laser-based-scalpel-may-revolutionize-brain-cancer-surgery-255492